1k6v: Difference between revisions
New page: left|200px<br /> <applet load="1k6v" size="450" color="white" frame="true" align="right" spinBox="true" caption="1k6v, resolution 2.00Å" /> '''LACK OF SYNERGY FOR... |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:1k6v.gif|left|200px]]<br /> | [[Image:1k6v.gif|left|200px]]<br /><applet load="1k6v" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="1k6v" size=" | |||
caption="1k6v, resolution 2.00Å" /> | caption="1k6v, resolution 2.00Å" /> | ||
'''LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE'''<br /> | '''LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE'''<br /> | ||
==Overview== | ==Overview== | ||
The three-dimensional structures of indinavir and three newly synthesized | The three-dimensional structures of indinavir and three newly synthesized indinavir analogs in complex with a multi-drug-resistant variant (L63P, V82T, I84V) of HIV-1 protease were determined to approximately 2.2 A resolution. Two of the three analogs have only a single modification of indinavir, and their binding affinities to the variant HIV-1 protease are enhanced over that of indinavir. However, when both modifications were combined into a single compound, the binding affinity to the protease variant was reduced. On close examination, the structural rearrangements in the protease that occur in the tightest binding inhibitor complex are mutually exclusive with the structural rearrangements seen in the second tightest inhibitor complex. This occurs as adaptations in the S1 pocket of one monomer propagate through the dimer and affect the conformation of the S1 loop near P81 of the other monomer. Therefore, structural rearrangements that occur within the protease when it binds to an inhibitor with a single modification must be accounted for in the design of inhibitors with multiple modifications. This consideration is necessary to develop inhibitors that bind sufficiently tightly to drug-resistant variants of HIV-1 protease to potentially become the next generation of therapeutic agents. | ||
==About this Structure== | ==About this Structure== | ||
1K6V is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] with ACT and XN2 as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http:// | 1K6V is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] with <scene name='pdbligand=ACT:'>ACT</scene> and <scene name='pdbligand=XN2:'>XN2</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1K6V OCA]. | ||
==Reference== | ==Reference== | ||
Line 15: | Line 14: | ||
[[Category: Human immunodeficiency virus 1]] | [[Category: Human immunodeficiency virus 1]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Schiffer, C | [[Category: Schiffer, C A.]] | ||
[[Category: ACT]] | [[Category: ACT]] | ||
[[Category: XN2]] | [[Category: XN2]] | ||
Line 23: | Line 22: | ||
[[Category: inhibitor recognition]] | [[Category: inhibitor recognition]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:30:57 2008'' |